title: Phenotypic screens targeting neurodegenerative diseases.
abstract: Neurodegenerative diseases affect millions of people worldwide, and the incidences increase as the population ages. Disease-modifying therapy that prevents or slows disease progression is still lacking, making neurodegenerative diseases an area of high unmet medical need. Target-based drug discovery for disease-modifying agents has been ongoing for many years, without much success due to incomplete understanding of the molecular mechanisms underlying neurodegeneration. Phenotypic screening, starting with a disease-relevant phenotype to screen for compounds that change the outcome of biological pathways rather than activities at certain specific targets, offers an alternative approach to find small molecules or targets that modulate the key characteristics of neurodegeneration. Phenotypic screens that focus on amelioration of disease-specific toxins, protection of neurons from degeneration, or promotion of neuroregeneration could be potential fertile grounds for discovering therapeutic agents for neurodegenerative diseases. In this review, we will summarize the progress of compound screening using these phenotypic-based strategies for this area, with a highlight on unique considerations for disease models, assays, and screening methodologies. We will further provide our perspectives on how best to use phenotypic screening to develop drug leads for neurodegenerative diseases.
authors: 1GlaxoSmithKline (China) R&D Company Limited, Neurodegeneration DPU, Shanghai, China.
authors: Minhua
authors: M
authors: Zhang
authors: Guangrui
authors: G
authors: Luo
authors: Yanjiao
authors: Y
authors: Zhou
authors: Shaohui
authors: S
authors: Wang
authors: Zhong
authors: Z
authors: Zhong
mesh_terms: D000818:Animals; D055808:Drug Discovery / Q000379:methods*; D004353:Drug Evaluation, Preclinical / Q000379:methods*; D006801:Humans; D019636:Neurodegenerative Diseases / Q000188:drug therapy* / Q000209:etiology; D010641:Phenotype
keywords: neurodegenerative diseases; phenotypic screening; technical considerations